Sarepta Therapeutics,, Inc. Common Stock | SRPT

Daily Technical Analysis of Sarepta Therapeutics,, Inc. Common Stock

Sarepta Therapeutics is up a bit on the day, funds flowing in kept the price up 2.88% since yesterday.

Currently SRPT isn't at a clear support/resistance line that seems tradable. But we can consider it's momentum, Sarepta Therapeutics has seen a lot of selling over the last year which hasn't let up, this thing has really been sliding. People who bought the Biotechnology company have lost -71.76 percent over the last 12 months, not great! I would wait until it get to a better support level before rolling the dice on this one. SRPT might find some support at the 125.34 level, buyers might push the price back up from here. But it's not very clear what will happen.

Analyst Ratings for Sarepta Therapeutics By Price Target And Rating

The analysts are pretty neutral on Sarepta Therapeutics right now, so not much useful information here. The current Analysts Sentiment Score is 1.86. Most companies range between (-200 to 200).

Here's a break down of the latest rating changes. Needham & Company LLC dropped their price target by -1.78% to $166.00 on 2024-02-29. On 2024-02-29 Barclays increased their price target by 31.21% to $185.00. On 2024-02-29 Citigroup increased their price target by 7.5% to $172.00. Cantor Fitzgerald announced that they are reiterating a rating of Neutral on 2024-02-29 and they set their price target at $128.00. On 2024-02-29 there was confirmation of the previous rating by Wedbush which was Outperform and provided a price target of $224.00. Royal Bank of Canada gave a boost to their price target and moved to $157.00 from $151.00 on 2024-02-29. Evercore ISI provided a price target boost of 27.78% to $138.00 from $108.00 on 2024-02-20. Mizuho gave a boost to their price target and moved to $145.00 from $130.00 on 2024-02-14. BMO Capital Markets initiated a rating of Outperform on 2024-01-31 and provided a price target of $170.00. On 2023-12-12 Deutsche Bank Aktiengesel started covering Sarepta Therapeutics with a rating of Buy and added a price target of $109.00.

Earnings Per Share (EPS) Estimates By Year and Quarter

Short interest for Sarepta Therapeutics

We take into account several different measures of short interest to create a composite score. These measures are shown in the chart below. Short selling is when investors are betting against a stock. We compile these factors to create a dynamic Short Score - this can indicate poor sentiment, internal problems with a company or industry and the anticipation of future price declines. We look at the short interest percent, days to cover, the rate of change and total shares sold short.

Social Sentiment for Sarepta Therapeutics

Social Sentiment is an aggregation of several different factors such as news, articles, blogs, user content, ratings, etc. Which is shown in the chart below. It may become predictive of a reversal if price and the sentiment diverge. Broader market forces may push prices up or down but if market participants maintain a different view on a specific stock, it may be taken as an opportunity to buy or sell in those cases.